[go: up one dir, main page]

CY1109748T1 - Κινοξαλινυλ μακροκυκλικοι αναστολεις πρωτεασης σερινης ηπατιτιδας c - Google Patents

Κινοξαλινυλ μακροκυκλικοι αναστολεις πρωτεασης σερινης ηπατιτιδας c

Info

Publication number
CY1109748T1
CY1109748T1 CY20101100107T CY101100107T CY1109748T1 CY 1109748 T1 CY1109748 T1 CY 1109748T1 CY 20101100107 T CY20101100107 T CY 20101100107T CY 101100107 T CY101100107 T CY 101100107T CY 1109748 T1 CY1109748 T1 CY 1109748T1
Authority
CY
Cyprus
Prior art keywords
present
compounds
formula
usitis
kinoxalinyl
Prior art date
Application number
CY20101100107T
Other languages
English (en)
Inventor
Suanne Nakajima
Ying Sun
Datong Tang
Gouyou Xu
Brian Porter
Yat Sun Or
Zhe Wang
Zhenwei Miao
Original Assignee
Enanta Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Enanta Pharmaceuticals, Inc. filed Critical Enanta Pharmaceuticals, Inc.
Publication of CY1109748T1 publication Critical patent/CY1109748T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)

Abstract

Η παρούσα εφεύρεση αφορά ενώσεις του Τύπου (I) ή (II), ή φαρμακευτικώς αποδεκτό άλας, εστέρα, ή προφάρμακο αυτών: τύπος (I), τύπος (II): που αναστέλλουν την δραστικότητα πρωτεάσης σερίνης, ιδιαιτέρως την δραστικότητα της NS3-NS4A πρωτεάσης του ιού ηπατίτιδας C (HCV). Συνεπώς, οι ενώσεις της παρούσας εφεύρεσης εμπλέκονται με τον κύκλο ζωής του ιού ηπατίτιδας C και είναι επίσης χρήσιμες ως αντιϊικοί παράγοντες. Η παρούσα εφεύρεση περαιτέρω αφορά φαρμακευτικές συνθέσεις που περιλαμβάνουν τις προαναφερόμενες ενώσεις για χορήγηση σε ένα υποκείμενο που πάσχει από HCV μόλυνση. Η εφεύρεση επίσης αφορά μεθόδους θεραπείας μιας HCV μόλυνσης σε ένα υποκείμενο με χορήγηση μιας φαρμακευτικής σύνθεσης που περιλαμβάνει τις ενώσεις της παρούσας εφεύρεσης.
CY20101100107T 2003-04-18 2010-02-04 Κινοξαλινυλ μακροκυκλικοι αναστολεις πρωτεασης σερινης ηπατιτιδας c CY1109748T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41875903A 2003-04-18 2003-04-18
EP04750236A EP1615613B1 (en) 2003-04-18 2004-04-16 Quinoxalinyl macrocyclic hepatitis c serine protease inhibitors

Publications (1)

Publication Number Publication Date
CY1109748T1 true CY1109748T1 (el) 2014-09-10

Family

ID=33309537

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20101100107T CY1109748T1 (el) 2003-04-18 2010-02-04 Κινοξαλινυλ μακροκυκλικοι αναστολεις πρωτεασης σερινης ηπατιτιδας c

Country Status (16)

Country Link
EP (2) EP1615613B1 (el)
JP (2) JP4778893B2 (el)
KR (1) KR101031825B1 (el)
CN (1) CN1788006A (el)
AT (1) ATE447573T1 (el)
AU (2) AU2004231987C1 (el)
CA (1) CA2522561C (el)
CY (1) CY1109748T1 (el)
DE (1) DE602004023924D1 (el)
DK (1) DK1615613T3 (el)
ES (2) ES2335887T3 (el)
HK (2) HK1083337A1 (el)
PL (1) PL1615613T3 (el)
PT (1) PT1615613E (el)
SI (1) SI1615613T1 (el)
WO (1) WO2004093798A2 (el)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY140680A (en) 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
TWI280964B (en) 2003-09-26 2007-05-11 Schering Corp Macrocyclic inhibitors of hepatitis C virus NS3 serine protease
EA014584B1 (ru) 2004-01-30 2010-12-30 Медивир Аб Ингибиторы ns-3 сериновой протеазы hcv
AU2005212257A1 (en) * 2004-02-04 2005-08-25 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
CA2553879C (en) 2004-02-20 2011-02-22 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
EP1805187A1 (en) * 2004-10-21 2007-07-11 Pfizer, Inc. Inhibitors of hepatitis c virus protease, and compositions and treatments using the same
US7323447B2 (en) 2005-02-08 2008-01-29 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7592336B2 (en) 2005-05-10 2009-09-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7608592B2 (en) 2005-06-30 2009-10-27 Virobay, Inc. HCV inhibitors
US7601686B2 (en) 2005-07-11 2009-10-13 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CA2615666C (en) * 2005-07-25 2014-08-26 Intermune, Inc. Novel macrocyclic inhibitors of hepatitis c virus replication
PE20070211A1 (es) 2005-07-29 2007-05-12 Medivir Ab Compuestos macrociclicos como inhibidores del virus de hepatitis c
EP1915378A4 (en) 2005-08-12 2009-07-22 Boehringer Ingelheim Int VIRUS POLYMERASE INHIBITORS
AR055395A1 (es) 2005-08-26 2007-08-22 Vertex Pharma Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
US7772183B2 (en) 2005-10-12 2010-08-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7741281B2 (en) 2005-11-03 2010-06-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7816348B2 (en) 2006-02-03 2010-10-19 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
US20070281884A1 (en) * 2006-06-06 2007-12-06 Ying Sun Macrocyclic oximyl hepatitis C protease inhibitors
UY30437A1 (es) * 2006-06-26 2008-01-31 Enanta Pharm Inc Quinoxalinil macroceclicos inhibidores de serina proteasa del virus de la hepatitis c
US7935670B2 (en) 2006-07-11 2011-05-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
BRPI0716060A2 (pt) 2006-08-17 2013-09-17 Boehringer Ingelheim Int inibidores de polimerase viral.
US20080107623A1 (en) * 2006-11-01 2008-05-08 Bristol-Myers Squibb Company Inhibitors of Hepatitis C Virus
US8343477B2 (en) 2006-11-01 2013-01-01 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus
US7772180B2 (en) 2006-11-09 2010-08-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7888464B2 (en) 2006-11-16 2011-02-15 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CN101568543B (zh) * 2006-11-16 2012-06-06 百时美施贵宝公司 大环肽作为丙型肝炎病毒抑制剂
US8003604B2 (en) 2006-11-16 2011-08-23 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7763584B2 (en) 2006-11-16 2010-07-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
AU2008205116A1 (en) * 2007-01-08 2008-07-17 Phenomix Corporation Macrocyclic hepatitis C protease inhibitors
AR067180A1 (es) * 2007-06-29 2009-09-30 Gilead Sciences Inc Compuestos antivirales
AP2874A (en) 2007-06-29 2014-03-31 Gilead Sciences Inc Antiviral compounds
AU2008271117B2 (en) 2007-06-29 2013-10-24 Gilead Sciences, Inc. Antiviral compounds
CA2693997C (en) 2007-08-03 2013-01-15 Pierre L. Beaulieu Viral polymerase inhibitors
CN101977621A (zh) 2007-12-05 2011-02-16 益安药业 氟化三肽hcv丝氨酸蛋白酶抑制剂
EP2234977A4 (en) 2007-12-19 2011-04-13 Boehringer Ingelheim Int VIRAL POLYMERASE INHIBITORS
US8202996B2 (en) 2007-12-21 2012-06-19 Bristol-Myers Squibb Company Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide
MX2010008523A (es) * 2008-02-04 2010-08-31 Idenix Pharmaceuticals Inc Inhibidores macrociclicos de serina proteasa.
US8163921B2 (en) 2008-04-16 2012-04-24 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
JP5529120B2 (ja) 2008-05-29 2014-06-25 ブリストル−マイヤーズ スクイブ カンパニー Ｃ型肝炎ウイルス阻害剤
US7964560B2 (en) 2008-05-29 2011-06-21 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8207341B2 (en) 2008-09-04 2012-06-26 Bristol-Myers Squibb Company Process or synthesizing substituted isoquinolines
UY32099A (es) * 2008-09-11 2010-04-30 Enanta Pharm Inc Inhibidores macrocíclicos de serina proteasas de hepatitis c
AU2012201327B2 (en) * 2008-09-11 2014-06-26 Abbvie Ireland Unlimited Company Macrocyclic hepatitis C serine protease inhibitors
US8044087B2 (en) 2008-09-29 2011-10-25 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8563505B2 (en) 2008-09-29 2013-10-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8283310B2 (en) 2008-12-15 2012-10-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
MX2011007195A (es) 2009-01-07 2013-07-12 Scynexis Inc Derivado de ciclosporina para el uso en el tratamiento de infección de virus de hepatitis c (vhc) y virus de inmunodeficiencia humana (vih).
EP2417134B1 (en) 2009-04-08 2017-05-17 Idenix Pharmaceuticals LLC. Macrocyclic serine protease inhibitors
JP5639155B2 (ja) 2009-05-13 2014-12-10 エナンタ ファーマシューティカルズ インコーポレイテッド Ｃ型肝炎ウイルスインヒビターとしての大環状化合物
US8232246B2 (en) 2009-06-30 2012-07-31 Abbott Laboratories Anti-viral compounds
AR077712A1 (es) 2009-08-05 2011-09-14 Idenix Pharmaceuticals Inc Inhibidores de serina proteasa macrociclica
EA201290128A1 (ru) * 2009-09-28 2013-01-30 Интермьюн, Инк. Новые макроциклические ингибиторы репликации вируса гепатита с
NZ608720A (en) 2010-09-21 2015-03-27 Enanta Pharm Inc Macrocyclic proline derived hcv serine protease inhibitors
WO2012054874A1 (en) * 2010-10-22 2012-04-26 Intermune, Inc. Novel macrocyclic inhibitors of hepatitis c virus replication
MX2013007698A (es) 2010-12-30 2013-08-15 Abbvie Inc Inhibidores de serina proteasa de hepatitis c macrociclicos de fenantridina.
US8937041B2 (en) 2010-12-30 2015-01-20 Abbvie, Inc. Macrocyclic hepatitis C serine protease inhibitors
US9353100B2 (en) 2011-02-10 2016-05-31 Idenix Pharmaceuticals Llc Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating HCV infections
US8957203B2 (en) 2011-05-05 2015-02-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
US8691757B2 (en) 2011-06-15 2014-04-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
UA119315C2 (uk) 2012-07-03 2019-06-10 Гіліад Фармассет Елелсі Інгібітори вірусу гепатиту с
WO2014062196A1 (en) 2012-10-19 2014-04-24 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
EP2914598B1 (en) 2012-11-02 2017-10-18 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US9643999B2 (en) 2012-11-02 2017-05-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2014070964A1 (en) 2012-11-02 2014-05-08 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
EP2914614B1 (en) 2012-11-05 2017-08-16 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US9434738B2 (en) * 2013-01-10 2016-09-06 Bristol-Myers Squibb Company Macrocyclic benzofuran and azabenzofuran compounds for the treatment of hepatitis C
US9580463B2 (en) 2013-03-07 2017-02-28 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
SG10201913593WA (en) * 2013-03-13 2020-02-27 Harvard College Stapled and stitched polypeptides and uses thereof
EP2970335B1 (en) 2013-03-15 2019-05-08 Gilead Sciences, Inc. Macrocyclic and bicyclic inhibitors of hepatitis c virus
BR112015031277A2 (pt) 2013-06-14 2017-09-19 Harvard College Moduladores do receptor de insulina de polipeptídeos estabilizados, análogos de insulina, composições farmacêuticas compreendendo os referidos polipeptídeos e métodos de preparação e usos dos mesmos
EP3089757A1 (en) 2014-01-03 2016-11-09 AbbVie Inc. Solid antiviral dosage forms
EP2899207A1 (en) 2014-01-28 2015-07-29 Amikana.Biologics New method for testing HCV protease inhibition
US11066416B2 (en) 2016-02-04 2021-07-20 The Johns Hopkins University Rapafucin derivative compounds and methods of use thereof
CN108697701B (zh) 2016-02-04 2021-10-26 约翰霍普金斯大学 平衡型核苷转运蛋白1的抑制剂Rapadocin及其用途
CN108697729B (zh) 2016-02-04 2023-05-09 约翰霍普金斯大学 新型GLUT抑制剂rapaglutin及其用途
SG11202001162TA (en) 2017-09-07 2020-03-30 Fog Pharmaceuticals Inc Agents modulating beta-catenin functions and methods thereof
US20220372014A1 (en) * 2019-10-01 2022-11-24 The Johns Hopkins University Neuroprotective compounds and methods of use thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998013482A1 (en) * 1996-09-27 1998-04-02 Merck & Co., Inc. Detergent-free hepatitis c protease
US5861297A (en) 1996-09-27 1999-01-19 Merck & Co., Inc. Detergent-free hepatitis C protease
PT1003775E (pt) 1997-08-11 2005-07-29 Boehringer Ingelheim Ca Ltd Peptidos inibidores da hepatite c
EP1066247B1 (en) 1998-03-31 2006-11-22 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease
US6323180B1 (en) * 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
US6086469A (en) * 1998-10-29 2000-07-11 Dec International, Inc. Method and means for conveying and processing an extruded sausage strand
UA74546C2 (en) * 1999-04-06 2006-01-16 Boehringer Ingelheim Ca Ltd Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition

Also Published As

Publication number Publication date
ES2535147T3 (es) 2015-05-06
JP2007525455A (ja) 2007-09-06
SI1615613T1 (sl) 2010-03-31
EP2143727B1 (en) 2015-01-21
ATE447573T1 (de) 2009-11-15
AU2010200619A1 (en) 2010-03-11
CA2522561A1 (en) 2004-11-04
EP1615613B1 (en) 2009-11-04
KR101031825B1 (ko) 2011-04-29
AU2004231987C1 (en) 2010-09-30
CN1788006A (zh) 2006-06-14
KR20050123170A (ko) 2005-12-29
PT1615613E (pt) 2010-02-09
JP2011178781A (ja) 2011-09-15
WO2004093798A3 (en) 2005-12-08
JP4778893B2 (ja) 2011-09-21
WO2004093798A2 (en) 2004-11-04
EP2143727A1 (en) 2010-01-13
CA2522561C (en) 2012-07-17
HK1083337A1 (en) 2006-06-30
HK1140214A1 (en) 2010-10-08
ES2335887T3 (es) 2010-04-06
PL1615613T3 (pl) 2010-04-30
AU2004231987B2 (en) 2009-11-19
AU2010200619B2 (en) 2013-11-07
AU2004231987A1 (en) 2004-11-04
DK1615613T3 (da) 2010-03-22
EP1615613A2 (en) 2006-01-18
DE602004023924D1 (en) 2009-12-17
EP1615613A4 (en) 2007-02-14

Similar Documents

Publication Publication Date Title
CY1109748T1 (el) Κινοξαλινυλ μακροκυκλικοι αναστολεις πρωτεασης σερινης ηπατιτιδας c
WO2004113365A3 (en) Hepatitis c serine protease tri-peptide inhibitors
HK1101402A1 (en) Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
WO2005007681A3 (en) Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
WO2008002924A3 (en) Quinoxalinyl macrocyclic hepatitis c virus serine protease inhibitors
WO2004072243A3 (en) Macrocyclic hepatitis c serine protease inhibitors
ATE349463T1 (de) Verbrückte bizyklische serinproteaseinhibitoren
WO2005037860A3 (en) Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
TW200510391A (en) Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
WO2009053828A3 (en) P3 hydroxyamino macrocyclic hepatitis c serine protease inhibitors
WO2007143694A3 (en) Macrocyclic oximyl hepatitis c protease inhibitors
MX2010006209A (es) Derivados de quinoxalinilo.
WO2009076173A3 (en) Fluorinated tripeptide hcv serine protease inhibitors
WO2008019303A3 (en) Pyridazinonyl macrocyclic hepatitis c serine protease inhibitors
WO2008022006A3 (en) Arylalkoxyl hepatitis c virus protease inhibitors
UA102677C2 (uk) Хіноксалінвмісні сполуки як інгібітори вірусу гепатиту с
WO2008021956A3 (en) Acylaminoheteroaryl hepatitis c virus protease inhibitors
WO2008021960A3 (en) Triazolyl macrocyclic hepatitis c serine protease inhibitors
WO2008019266A3 (en) Acyclic, pyridazinone-derived hepatitis c serine protease inhibitors
WO2005035525A3 (en) 2-amido-4-aryloxy-1-carbonylpyrrolidine derivatives as inhibitors of serine proteases, particularly hcv ns3-ns4a protease
MX2010006518A (es) Inhibidores de serina proteasa de hepatitis c de oximil macrociclica.
WO2008021871A3 (en) Triazolyl acyclic hepatitis c serine protease inhibitors
MX2010010276A (es) Compuestos macrociclicos fluorinados como inhibidores del virus de hepatitis c.
WO2009076166A3 (en) Oximyl hcv serine protease inhibitors
WO2008019289A3 (en) Tetrazolyl macrocyclic hepatitis c serine protease inhibitors